Small molecule · Modulator of vitamin D receptor (VDR) · developed by Organon Usa
Calcifediol is a prohormone of calcitriol, the active form of vitamin D3. It is converted mainly in the kidney by CYP27B1 to calcitriol, which binds the vitamin D receptor to increase intestinal calcium and phosphorus absorption and reduce parathyroid hormone synthesis. It is studied in chronic kidney disease, secondary hyperparathyroidism, vitamin D deficiency and COVID-19.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 19, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03588884 | Phase 4 | Secondary Hyperparathyroidism Due to Renal Causes | Completed | OPK |
| NCT05543928 | Phase 3 | Chronic Kidney Disease stage3 | Terminated | OPK |
| NCT02282813 | Phase 3 | Chronic Kidney Disease | Completed | OPK |
| NCT04551911 | Phase 2 | COVID-19 | Completed | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Kidney DiseaseChronic Kidney Disease stage3Chronic Kidney Disease stage4CKD Stage 3CKD Stage 4CoronavirusCOVID-19Hyperparathyroidism, SecondarySARS-CoV2 InfectionSecondary HyperparathyroidismSecondary Hyperparathyroidism Due to Renal CausesVitamin D DeficiencyVitamin D Insufficiency
Updated Oct 25, 2026.